# A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

> **NCT01497119** · PHASE2 · TERMINATED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 88 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** JNJ-39758979, 300 mg
- **DRUG:** JNJ-39758979, 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01497119
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** This study was terminated prematurely due to 2 cases of agranulocytosis.
- **Last updated:** 2015-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497119, "A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01497119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*